Evidence map›Paper›PMID 27981366›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2017

A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment.

Maria Browall, Yvonne Brandberg, Salmir Nasic, Per Rydberg, Jonas Bergh, Andreas Rydén, Hanjing Xie, Irene Eriksson, Yvonne Wengström

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 7 pooled it
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 7 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Effects of a 4Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Maria BrowallDepartment of Neurobiology, Care Science and Society, Division of Nursing, Karolinska Institutet, Huddinge, Sweden. maria.brovall@his.se.ORCID 0000-0003-0976-531X
Yvonne BrandbergDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Salmir NasicResearch and Development Centre, Skaraborg Hospital, Skövde, Sweden.
Per RydbergDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Jonas BerghRadiumhemmet and Cancer Centre Karolinska, Karolinska University Hospital, Stockholm, Sweden.
Andreas RydénDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Hanjing XieRadiumhemmet and Cancer Centre Karolinska, Karolinska University Hospital, Stockholm, Sweden.
Irene ErikssonSchool of Health and Education, University of Skövde, Skövde, Sweden.
Yvonne WengströmDepartment of Neurobiology, Care Science and Society, Division of Nursing, Karolinska Institutet, Huddinge, Sweden.
Karolinska Institutet · SEKarolinska University Hospital · SEUniversity of Skövde · SESkaraborg Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim was to prospectively map symptom clusters in patients with stage I-IIIa breast cancer during standard chemotherapy treatment in a randomised study.

methodsParticipants completed the Memorial Symptom Assessment Scale (MSAS) at baseline, day 12 after the first and third cycle of FEC 75 or FEC 100, and day 12 after the last cycle of Taxotere. Cut-off values for symptom scores, a mean value based on each individual reporting a symptom including occurrence, frequency, severity and distress for inclusion in analysis, were determined.

resultsThe symptom burden cluster analysis was conducted in two steps and included symptoms with high frequency and high levels of distress. The factor analysis revealed three symptom clusters; physical, gastro (phys/gastro) and emotional, with core symptoms that remained stable over time. The most prevalent symptoms for the total sample during all cycles were as follows: lack of energy (range between 48 and 90%), feeling sad (48-79%), difficulty sleeping (54-78%), difficulty concentrating (53-74%), worrying (54-74%) and pain (29-67%).

conclusionIn summary, we have prospectively established that symptom clusters remain stable over time with a basis of core symptoms. This knowledge will aid in the development of effective core symptom-focused interventions to minimise symptom burden for patients treated with chemotherapy for breast cancer.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCluster AnalysisCyclophosphamideEpirubicinFemaleFluorouracilHumansMiddle AgedNeoplasm StagingPainPrevalenceProspective StudiesSyndromeCyclophosphamideEpirubicinFluorouracilBreast cancerChemotherapyPatient reported outcome measuresSymptomSymptom cluster

Identifiers

PMID27981366
PMCPMC5378737
OpenAlexW2563033909

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.